Clinical Trial Update: A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating GLS-010 plus platinum-containing chemotherapy with or without bevacizumab as first-line therapy for persistent, recurrent, o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• GLS-010
• Platinum-containing chemotherapy

Snippet

Sponsor: Guangzhou Gloria Biosciences Co., Ltd. | Conditions: Persistent, Recurrent, or Metastatic Cervical Cancer | Phase 3 | Status: NOT_YET_RECRUITING